US20240016738A1 - Lipid nanoparticles - Google Patents
Lipid nanoparticles Download PDFInfo
- Publication number
- US20240016738A1 US20240016738A1 US18/196,235 US202318196235A US2024016738A1 US 20240016738 A1 US20240016738 A1 US 20240016738A1 US 202318196235 A US202318196235 A US 202318196235A US 2024016738 A1 US2024016738 A1 US 2024016738A1
- Authority
- US
- United States
- Prior art keywords
- lnp
- mol
- lipid
- mrna
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 94
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 17
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 86
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 32
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 32
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 32
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 27
- 229960005486 vaccine Drugs 0.000 claims abstract description 27
- 229930182558 Sterol Natural products 0.000 claims abstract description 23
- 150000003432 sterols Chemical class 0.000 claims abstract description 23
- 235000003702 sterols Nutrition 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims description 38
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 26
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 235000012000 cholesterol Nutrition 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 230000001476 alcoholic effect Effects 0.000 claims description 11
- 210000004185 liver Anatomy 0.000 claims description 10
- 108010029697 CD40 Ligand Proteins 0.000 claims description 9
- 102100032937 CD40 ligand Human genes 0.000 claims description 9
- 210000000952 spleen Anatomy 0.000 claims description 9
- 102100025221 CD70 antigen Human genes 0.000 claims description 8
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 8
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 6
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 6
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000002519 immonomodulatory effect Effects 0.000 claims description 6
- 239000003125 aqueous solvent Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 claims description 3
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 claims description 3
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims description 3
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 claims description 3
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 claims description 3
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 claims description 3
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 claims description 3
- BDCFUHIWJODVNG-UHFFFAOYSA-N Desmosterol Natural products C1C=C2CC(O)C=CC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 BDCFUHIWJODVNG-UHFFFAOYSA-N 0.000 claims description 3
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 3
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims description 3
- HRNVWBIKQMSFHI-UHFFFAOYSA-N Nicasterol Natural products CC1(C)C(CC)C1CC(C)C1C2(C)CCC3C4(C)CCC(O)CC4=CCC3C2CC1 HRNVWBIKQMSFHI-UHFFFAOYSA-N 0.000 claims description 3
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims description 3
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 claims description 3
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims description 3
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 claims description 3
- 235000000431 campesterol Nutrition 0.000 claims description 3
- 150000001783 ceramides Chemical class 0.000 claims description 3
- AVSXSVCZWQODGV-DPAQBDIFSA-N desmosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 AVSXSVCZWQODGV-DPAQBDIFSA-N 0.000 claims description 3
- 150000001982 diacylglycerols Chemical class 0.000 claims description 3
- 125000005265 dialkylamine group Chemical group 0.000 claims description 3
- 150000001985 dialkylglycerols Chemical class 0.000 claims description 3
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims description 3
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 150000008103 phosphatidic acids Chemical class 0.000 claims description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 3
- 235000015500 sitosterol Nutrition 0.000 claims description 3
- 229950005143 sitosterol Drugs 0.000 claims description 3
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 claims description 3
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims description 3
- 235000016831 stigmasterol Nutrition 0.000 claims description 3
- 229940032091 stigmasterol Drugs 0.000 claims description 3
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002163 immunogen Effects 0.000 abstract description 12
- 230000028993 immune response Effects 0.000 abstract description 11
- 206010028980 Neoplasm Diseases 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 7
- 201000011510 cancer Diseases 0.000 abstract description 6
- 208000035473 Communicable disease Diseases 0.000 abstract description 4
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 230000003389 potentiating effect Effects 0.000 abstract description 2
- 239000000427 antigen Substances 0.000 description 27
- 102000036639 antigens Human genes 0.000 description 27
- 108091007433 antigens Proteins 0.000 description 27
- 239000002202 Polyethylene glycol Substances 0.000 description 23
- 229920001223 polyethylene glycol Polymers 0.000 description 23
- 229920002477 rna polymer Polymers 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 201000010099 disease Diseases 0.000 description 18
- 230000005847 immunogenicity Effects 0.000 description 17
- 238000001990 intravenous administration Methods 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 9
- 102000053602 DNA Human genes 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 230000005867 T cell response Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- ZKVLEFBKBNUQHK-UHFFFAOYSA-N helium;molecular nitrogen;molecular oxygen Chemical compound [He].N#N.O=O ZKVLEFBKBNUQHK-UHFFFAOYSA-N 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 4
- MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229960004956 glycerylphosphorylcholine Drugs 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940126582 mRNA vaccine Drugs 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000002516 postimmunization Effects 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- JTERLNYVBOZRHI-PPBJBQABSA-N (2-aminoethoxy)[(2r)-2,3-bis[(5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoyloxy]propoxy]phosphinic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC JTERLNYVBOZRHI-PPBJBQABSA-N 0.000 description 2
- XLKQWAMTMYIQMG-SVUPRYTISA-N (2-{[(2r)-2,3-bis[(4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoyloxy]propyl phosphonato]oxy}ethyl)trimethylazanium Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC XLKQWAMTMYIQMG-SVUPRYTISA-N 0.000 description 2
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- SSCDRSKJTAQNNB-DWEQTYCFSA-N 1,2-di-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphoethanolamine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC SSCDRSKJTAQNNB-DWEQTYCFSA-N 0.000 description 2
- LZLVZIFMYXDKCN-QJWFYWCHSA-N 1,2-di-O-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC LZLVZIFMYXDKCN-QJWFYWCHSA-N 0.000 description 2
- XXKFQTJOJZELMD-JICBSJGISA-N 1,2-di-[(9Z,12Z,15Z)-octadecatrienoyl]-sn-glycero-3-phosphocholine Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC XXKFQTJOJZELMD-JICBSJGISA-N 0.000 description 2
- DSNRWDQKZIEDDB-SQYFZQSCSA-N 1,2-dioleoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-SQYFZQSCSA-N 0.000 description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 2
- WTJKGGKOPKCXLL-VYOBOKEXSA-N 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC WTJKGGKOPKCXLL-VYOBOKEXSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XLPHMKQBBCKEFO-DHYROEPTSA-N 2-azaniumylethyl [(2r)-2,3-bis(3,7,11,15-tetramethylhexadecanoyloxy)propyl] phosphate Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C XLPHMKQBBCKEFO-DHYROEPTSA-N 0.000 description 2
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 2
- WIHSZOXPODIZSW-KJIWEYRQSA-N PE(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)) Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC WIHSZOXPODIZSW-KJIWEYRQSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- NJFCSWSRXWCWHV-USYZEHPZSA-N [(2R)-2,3-bis(octadec-1-enoxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCC=COC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC=CCCCCCCCCCCCCCCCC NJFCSWSRXWCWHV-USYZEHPZSA-N 0.000 description 2
- SUTHKQVOHCMCCF-QZNUWAOFSA-N [(2r)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-docosa-2,4,6,8,10,12-hexaenoyloxypropyl] docosa-2,4,6,8,10,12-hexaenoate Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)C=CC=CC=CC=CC=CC=CCCCCCCCCC SUTHKQVOHCMCCF-QZNUWAOFSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- VLBPIWYTPAXCFJ-XMMPIXPASA-N lysophosphatidylcholine O-16:0/0:0 Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C VLBPIWYTPAXCFJ-XMMPIXPASA-N 0.000 description 2
- 108700021021 mRNA Vaccine Proteins 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- IUVFCFQZFCOKRC-IPKKNMRRSA-M sodium;[(2r)-2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl] 2,3-dihydroxypropyl phosphate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC IUVFCFQZFCOKRC-IPKKNMRRSA-M 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 1
- JFBCSFJKETUREV-UHFFFAOYSA-N 1,2 ditetradecanoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCC JFBCSFJKETUREV-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 1
- 102100034980 ICOS ligand Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 208000001455 Zika Virus Infection Diseases 0.000 description 1
- 208000035332 Zika virus disease Diseases 0.000 description 1
- 208000020329 Zika virus infectious disease Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- -1 cationic lipids Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- IZGYIFFQBZWOLJ-CKAACLRMSA-N phaseic acid Chemical compound C1C(=O)C[C@@]2(C)OC[C@]1(C)[C@@]2(O)C=CC(/C)=C\C(O)=O IZGYIFFQBZWOLJ-CKAACLRMSA-N 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Definitions
- the present invention relates to the field of lipid nanoparticles (LNP); more specifically comprising an ionisable lipid, a phospholipid, a sterol, a PEG lipid and one or more nucleic acids.
- LNP's of the present invention are characterized in having a minimal average diameter of about 140 nm, thereby inducing a more potent immune response.
- the present invention provides use of the LNPs for immunogenic delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in vaccines, such as for the treatment of cancer or infectious diseases. Finally, methods are provided for preparing such LNP's.
- lipid-based nanoparticle compositions such as lipoplexes and liposomes have been used as packaging vehicles for biologically active substances to allow transport into cells and/or intracellular compartments.
- These lipid-based nanoparticle compositions typically comprise a mixture of different lipids such as cationic lipids, ionizable lipids, phospholipids, structural lipids (such 30 as sterols or cholesterol), PEG (polyethylene glycol) lipids, . . . (as reviewed in Reichmuth et al., 2016). While many of such lipid compositions are known in the art, these typically have a small diameter, i.e. less than 200 nm, most often even less then 140 nm.
- Lipid based nanoparticles composed of a mixture of 4 lipids—a cationic or ionizable lipid, a 35 phospholipid, a sterol and a PEGylated lipid—have been developed for the non-immunogenic delivery of siRNA and mRNA to the liver after systemic administration.
- these LNPs typically display small sizes between 70-100 nm (Li et al., Nanoletters 2015; Thess et al. Mol ther 2015; Kauffman et al. Biomaterials 2016).
- LNPs have also been used for the immunogenic delivery of antigen encoding mRNA to the muscle or dermis (Richner et al. Cell 2017; Liang et al., Mol Ther 2017).
- small size (80-120 nm) LNPs are typically used since such small sizes have been shown to be crucial for immunogenicity, and small sized LNPs efficiently reach the injection draining lymph node, whereas larger LNP's are retained at the injection site (see Reichmuth et al., 2016).
- nanoparticles having a diameter of more than 140 nm, preferably even more than 200 nm are highly suitable for immunogenic delivery of mRNA upon systemic injection of the LNPs, which appears to correlate with an enhanced delivery of mRNA to the spleen.
- the present invention provides a lipid nanoparticle (LNP) comprising an ionisable lipid, a phospholipid, a sterol, a PEG lipid and one or more nucleic acid molecules; characterized in that said LNP has a minimal average diameter of about 140 nm; more preferably of about 200 nm.
- LNP lipid nanoparticle
- said ionisable lipid is a compound of formula (I):
- said ionisable lipid is a lipid of formula (I) wherein RCCO is ⁇ -D-Tocopherolsuccinoyl and X is
- said sterol is selected from the list comprising cholesterol, ergosterol, campesterol, oxysterol, antrosterol, desmosterol, nicasterol, sitosterol and stigmasterol; preferably cholesterol.
- said phospholipid is selected from the list comprising: 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-d
- said phospholipid is selected from the list comprising: 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), and mixtures thereof.
- DOPE 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine
- DOPC 1,2-Dioleoyl-sn-glycero-3-phosphocholine
- said PEG lipid is selected from the list comprising: PEG-modified phosphatidylethanolamine, a PEG-modified phosphatidic acid, a PEG-modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof.
- said one or more nucleic acid molecules are selected from (m)RNA and DNA molecules; more in particular one or more mRNA molecules.
- said one or more mRNA molecules are selected from the list comprising mRNA molecules encoding immunomodulatory polypeptides such as (add a list of all potential molecules) and/or mRNA molecules encoding antigen- and/or disease-specific mRNA.
- said one or more mRNA molecules are selected from the list comprising mRNA molecules encoding for CD40L, CD70 and caTLR4; and/or mRNA molecules encoding antigen- and/or disease-specific mRNA.
- the present invention also provides a pharmaceutical composition or a vaccine comprising one or more LNP's as defined herein.
- the present invention provides an LNP as defined herein or a pharmaceutical composition comprising one or more of such LNP's for use in human or veterinary medicine.
- the present invention provides a method for the preparation of an LNP according to the invention, comprising:
- said alcoholic solvent is ethanol and/or said aqueous solvent is water.
- the present invention further provides the use of an LNP, a pharmaceutical composition or a vaccine according to the present invention for the immunogenic delivery of said one or more nucleic acid molecules.
- the present invention provides an LNP, a pharmaceutical composition, or a vaccine as herein for use in the prevention and/or treatment of cancer or infectious diseases.
- FIG. 1 Immunogenicity of 140 nm versus 230 nm sized mRNA LNPs of identical composition.
- FIG. 2 Immunogenicity of OVA mRNA LNPs of different sizes after intravenous administration.
- FIG. 3 Immunogenicity of OVA mRNA LNPs of different sizes after single intravenous administration.
- FIG. 4 Percentages of OVA specific T cells upon intravenous administration of large sized LNPs containing OVA mRNA (10 ⁇ g) and TriMix mRNA (15 ⁇ g).
- FIG. 5 Comparison of the immunogenicity of 140 nm and 230 nm sized mRNA LNPs after one and two intravenous administrations of mRNA LNPs.
- FIG. 6 Comparison ratio spleen/liver expression of 100 nm and 230 nm sized mRNA LNPs
- FIGS. 7 A and 7 B Comparison of intravenous LNP mRNA vs intranodal administration
- FIG. 8 T cell responses to LNP mRNA formulations are long-live and boostable.
- FIG. 9 Comparison of immunogenicity and T cell response of LNPs having average sizes of 150 nm or 200 nm with LNPs having average size of 100 nm.
- the present invention provides LNP's having a diameter which is larger than generally used in the field, for which we have surprisingly found that these are highly suitable for immunogenic delivery of nucleic acid, specifically mRNA; for which we found a correlation with enhanced delivery to the spleen.
- immunogenic delivery of nucleic acid molecules means delivery of nucleic acid molecules to cells whereby contact with cells, internalization and/or expression inside the cells of said nucleic acids molecules result in induction of an immune response.
- the present invention provides a lipid nanoparticle (LNP) comprising an ionisable lipid, a phospholipid, a sterol, a PEG lipid and one or more nucleic acid molecules; characterized in that said LNP has a minimal diameter of about 140 nm; more preferably of about 200 nm.
- LNP lipid nanoparticle
- a lipid nanoparticle is generally known as a nanosized particle composed of a combination of different lipids. While many different types of lipids may be included in such LNP, the LNP's of the present invention are typically composed of a combination of an ionisable lipid, a phospholipid, a sterol and a PEG lipid.
- nanoparticle refers to any particle having a diameter making the particle suitable for systemic, in particular intravenous administration, of, in particular, nucleic acids, typically having a diameter of less than 1000 nanometers (nm).
- a nanoparticle has an average diameter of less than 600 nm. In some embodiments, a nanoparticle has an average diameter of less than 400 nm, but in any case the nanoparticles of the present invention have an average diameter of more than about 140 nm, more preferably more than about 200 nm. In a specific embodiment, the LNP's of the invention have a minimal average diameter of about 140 nm, about 150 nm, about 160 nm, about 170 nm, about 180 nm, about 190 nm or about 200 nm. For the sake of clarity, where a mixture of multiple LNP's is used, the minimal average diameter as referred to, is meant to be the minimal average diameter of said multiple LNP's.
- the mixture may contain some LNP's having a smaller average diameter than 140 nm, in as far as the remainder of the LNP's has an average diameter larger than 140 nm to result in an average minimum diameter of 140 nm of all LNP's together.
- the term “diameter” is meant to be the “average diameter”, even if it is not specifically specified.
- the term “ionisable” (or alternatively cationic) in the context of a compound or lipid means the presence of any uncharged group in said compound or lipid which is capable of dissociating by yielding an ion (usually an H + ion) and thus itself becoming positively charged.
- any uncharged group in said compound or lipid may yield an electron and thus becoming negatively charged.
- ionizable lipids are ionizable amino lipids which comprise 2 identical or different tails linked via an S—S bond, each of said tails comprising an ionizable amine such as represented by
- said ionisable lipid is a compound of formula (I):
- Such ionisable lipids are specifically represented by anyone of the following formulae:
- said ionisable lipid is a lipid of formula (I) wherein RCCO is ⁇ -D-Tocopherolsuccinoyl and X is
- sterol also known as steroid alcohol
- steroid alcohol is a subgroup of steroids that occur naturally in plants, animal and fungi, or can be produced by some bacteria.
- any suitable sterol may be used, such as selected from the list comprising cholesterol, ergosterol, campesterol, oxysterol, antrosterol, desmosterol, nicasterol, sitosterol and stigmasterol; preferably cholesterol.
- phospholipid is meant to be lipid molecule consisting of two hydrophobic fatty acid “tails” and a hydrophilic “head” consisting of a phosphate groups.
- the two components are most often joined together by a glycerol molecule, hence, in the phospholipid of the present invention is preferably a glycerol-phospholipid.
- the phosphate group is often modified with simple organic molecules such as choline (i.e. rendering a phosphocholine) or ethanolamine (i.e. rendering a phosphoethanolamine).
- Suitable phospholipids within the context of the invention can be selected from the list comprising: 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (PO
- said phospholipid is selected from the list comprising: 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), and mixtures thereof.
- DOPE 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine
- DOPC 1,2-Dioleoyl-sn-glycero-3-phosphocholine
- PEG lipid or alternatively “PEGylated lipid” is meant to be any suitable lipid modified with a PEG (polyethylene glycol) group.
- said PEG lipid is selected from the list comprising: PEG-modified phosphatidylethanolamine, a PEG-modified phosphatidic acid, a PEG-modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof.
- PEG lipids encompass C14-PEG2000 (1,2-Dimyristoyl-rac-glycerol, methoxypolyethylene glycol-2000 (DMG-PEG2000)) and C18-PEG5000 (1,2-Distearoyl-rac-glycerol, methoxypolyethylene glycol-5000 (DSG-PEG5000)).
- said LNP comprises about and between 10 mol % and 60 mol % of said ionisable lipid; preferably about and between 40 mol % and 60 mol %.
- said LNP comprises about and between 15 mol % and 50 mol % of sterol; preferably about and between 20 mol % and 40 mol %.
- said LNP comprises about and between 0.5 mol % and 10 mol % of said PEG lipid; preferably about and between 0.5 mol % and 5 mol %.
- said LNP comprises about and between 5 mol % and 40 mol % of said phospholipid; preferably about and between 5 mol % and 15 mol %.
- the LNP of the present invention comprises about and between 10 mol % and 60 mol % of said ionisable lipid; and/or about and between 15 mol % and 50 mol % of sterol; and/or about and between 0.5 mol % and 10 mol % of said PEG lipid; and/or about and between 5 mol % and 40 mol % of said phospholipid.
- the LNP of the present invention comprises about and between 40 mol % and 60 mol % of said ionisable lipid; and about and between 20 mol % and 40 mol % of sterol; and about and between 0.5 mol % and 5 mol % of said PEG lipid; and about and between 5 mol % and 15 mol % of said phospholipid.
- composition of particularly suitable LNP's in the context of the invention is represented in table 1:
- the inventors have found that the LNP's of the present invention are particularly suitable for the immunogenic delivery of nucleic acids; due to an increased targeting of the spleen in contrast to prior art known small LNP's which are mainly found to target the liver.
- LNP's comprising one or more nucleic acid molecules, such as DNA or RNA, more specifically mRNA.
- a “nucleic acid” in the context of the invention is a deoxyribonucleic acid (DNA) or preferably a ribonucleic acid (RNA), more preferably mRNA.
- Nucleic acids include according to the invention genomic DNA, cDNA, mRNA, recombinantly produced and chemically synthesized molecules.
- a nucleic acid may according to the invention be in the form of a molecule which is single stranded or double stranded and linear or closed covalently to form a circle.
- a nucleic can be employed for introduction into, i.e. transfection of, cells, for example, in the form of RNA which can be prepared by in vitro transcription from a DNA template. The RNA can moreover be modified before application by stabilizing sequences, capping, and polyadenylation.
- RNA relates to a molecule which comprises ribonucleotide residues and preferably being entirely or substantially composed of ribonucleotide residues.
- “Ribonucleotide” relates to a nucleotide with a hydroxyl group at the 2′-position of a ⁇ -D-ribofuranosyl group.
- the term includes double stranded RNA, single stranded RNA, isolated RNA such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA, as well as modified RNA that differs from naturally occurring RNA by the addition, deletion, substitution and/or alteration of one or more nucleotides.
- Such alterations can include addition of non-nucleotide material, such as to the end(s) of a RNA or internally, for example at one or more nucleotides of the RNA.
- Nucleotides in RNA molecules can also comprise non-standard nucleotides, such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These altered RNAs can be referred to as analogs.
- Nucleic acids may be comprised in a vector.
- vector includes any vectors known to the skilled person including plasmid vectors, cosmid vectors, phage vectors such as lambda phage, viral vectors such as adenoviral or baculoviral vectors, or artificial chromosome vectors such as bacterial artificial chromosomes (BAC), yeast artificial or analogs of naturally-occurring RNA.
- plasmid vectors cosmid vectors
- phage vectors such as lambda phage
- viral vectors such as adenoviral or baculoviral vectors
- artificial chromosome vectors such as bacterial artificial chromosomes (BAC), yeast artificial or analogs of naturally-occurring RNA.
- RNA includes and preferably relates to “mRNA” which means “messenger RNA” and relates to a “transcript” which may be produced using DNA as template and encodes a peptide or protein
- mRNA typically comprises a 5′ untranslated region (5-UTR), a protein or peptide coding region and a 3′ untranslated region (3′-UTR).
- mRNA has a limited halftime in cells and in vitro.
- mRNA is produced by in vitro transcription using a DNA template.
- the RNA is obtained by in vitro transcription or chemical synthesis.
- the in vitro transcription methodology is known to the skilled person. For example, there is a variety of in vitro transcription kits commercially available.
- said mRNA molecules are mRNA molecules encoding immune modulating proteins.
- mRNA molecules encoding immune modulating proteins is meant to be mRNA molecules encoding proteins that modify the functionality of antigen presenting cells; more in particular dendritic cells.
- Such molecules may be selected from the list comprising CD40L, CD70, caTLR4, IL-12p70, EL-selectin, CCR7, and/or 4-1 BBL, ICOSL, OX40L, IL-21; more in particular one or more of CD40L, CD70 and caTLR4.
- a preferred combination of immunostimulatory factors used in the methods of the invention is CD40L and caTLR4 (i.e. “DiMix”).
- the combination of CD40L, CD70 and caTLR4 immunostimulatory molecules is used, which is herein also named “TriMix”
- said mRNA molecules are mRNA molecules encoding antigen- and/or disease-specific proteins.
- the term “antigen” comprises any molecule, preferably a peptide or protein, which comprises at least one epitope that will elicit an immune response and/or against which an immune response is directed.
- an antigen in the context of the present invention is a molecule which, optionally after processing, induces an immune response, which is preferably specific for the antigen or cells expressing the antigen.
- an “antigen” relates to a molecule which, optionally after processing, is presented by MHC molecules and reacts specifically with T lymphocytes (T cells).
- the antigen is a target-specific antigen which can be a tumor antigen, or a bacterial, viral or fungal antigen.
- Said target-specific antigen can be derived from either one of: total mRNA isolated from (a) target cell(s), one or more specific target mRNA molecules, protein lysates of (a) target cell(s), specific proteins from (a) target cell(s), or a synthetic target-specific peptide or protein and synthetic mRNA or DNA encoding a target-specific antigen or its derived peptides.
- the LNP's of the present invention may comprise a single mRNA molecules, or they may comprise multiple mRNA molecules, such as a combination of one or more mRNA molecules encoding immune modulating proteins and/or one or more mRNA molecules encoding antigen- and/or disease-specific proteins.
- said mRNA molecules encoding immunomodulatory molecules may be combined with one or more mRNA molecules encoding antigen- and/or disease-specific proteins.
- the LNP's of the present invention may comprise mRNA molecules encoding the immunostimulatory molecules CD40L, CD70 and/or caTLR4 (such as Dimix or Trimix); in combination with one or more mRNA molecules encoding antigen- and/or disease-specific proteins.
- the LNP's of the present invention comprise an mRNA molecule encoding CD40L, CD70 and/or caTLR4; in combination with one or more mRNA molecules encoding antigen- and/or disease-specific proteins.
- the present invention provides a pharmaceutical composition comprising one or more LNP's as defined herein.
- Such pharmaceutical compositions are particularly suitable as a vaccine.
- the invention also provides a vaccine comprising one or more LNP's according to the present invention.
- vaccine in the context of the present invention, is meant to be any preparation intended to provide adaptive immunity (antibodies and/or T cell responses) against a disease.
- a vaccine as meant herein contains at least one mRNA molecule encoding an antigen to which an adaptive immune response is mounted.
- This antigen can be present in the format of a weakened or killed form of a microbe, a protein or peptide, or an antigen encoding a nucleic acid.
- An antigen in the context of this invention is meant to be a protein or peptide recognized by the immune system of a host as being foreign, thereby stimulating the production of antibodies against is, with the purpose of combating such antigens.
- Vaccines can be prophylactic (example: to prevent or ameliorate the effects of a future infection by any natural or “wild” pathogen), or therapeutic (example, to actively treat or reduce the symptoms of an ongoing disease).
- the administration of vaccines is called vaccination.
- the vaccine of the invention may be used for inducing an immune response, in particular an immune response against a disease-associated antigen or cells expressing a disease-associated antigen, such as an immune response against cancer. Accordingly, the vaccine may be used for prophylactic and/or therapeutic treatment of a disease involving a disease-associated antigen or cells expressing a disease-associated antigen, such as cancer.
- said immune response is a T cell response.
- the disease-associated antigen is a tumor antigen.
- the antigen encoded by the RNA comprised in the nanoparticles described herein preferably is a disease-associated antigen or elicits an immune response against a disease-associated antigen or cells expressing a disease-associated antigen.
- the LNP's and vaccines of the present invention are specifically intended for intravenous administration, i.e. the infusion of liquid substance directly into a vein.
- the intravenous route is the fastest way to deliver fluids and medications throughout the body, i.e. systemically.
- the present invention thus provides intravenous vaccines, as well as the use of the disclosed vaccines and LNP's for intravenous administration.
- the vaccines and LNP's of the present invention can thus be administered intravenously.
- the present invention also provides the use of the vaccines and LNP's according to the present invention; wherein the vaccine is administered intravenously.
- the present invention also provides the LNP's, pharmaceutical compositions and vaccines according to this invention for use in human or veterinary medicine.
- the use of the LNP's, pharmaceutical compositions and vaccines according to this invention for human or veterinary medicine is also intended.
- the invention provides a method for the prophylaxis and treatment of human and veterinary disorders, by administering the LNP's, pharmaceutical compositions and vaccines according to this invention to a subject in need thereof.
- the present invention further provides the use of an LNP, a pharmaceutical composition or a vaccine according to the present invention for the immunogenic delivery of said one or more nucleic acid molecules.
- This effect is specifically achieved using the larger LNP's of the invention, due to their preferential targeting to the spleen.
- the small-sized LNP's of the prior art where found to preferentially target the liver, thereby having little or no immunogenic effect.
- pharmaceutical compositions and vaccine of the present invention are highly useful in the treatment several human and veterinary disorders.
- the present invention provides the LNP's, pharmaceutical compositions and vaccines of the present invention for use in the treatment of cancer or infectious diseases.
- the present invention provides methods for the preparation of an LNP according to the present invention, comprising:
- the lipid components are combined in suitable concentrations in an alcoholic vehicle such as ethanol.
- an aqueous composition comprising the nucleic acid is added, and subsequently loaded in a microfluidic mixing device.
- microfluidic mixing is to achieve thorough and rapid mixing of multiple samples (i.e. lipid phase and nucleic acid phase) in a microscale device. Such sample mixing is typically achieved by enhancing the diffusion effect between the different species flows.
- samples i.e. lipid phase and nucleic acid phase
- microfluidic mixing devices can be used, such as for example reviewed in Lee et al., 2011.
- a particularly suitable microfluidic mixing device according to the present invention is the NanoAssemblr from Precision Nanosystems.
- the mixing parameters of such microfluidic mixing devices have a large impact on the characteristics of the obtained LNP's, specifically on the size thereof.
- the FR and FRR parameters are highly relevant.
- the total FR (Flow Rate) is a measure for the speed of microfluidic mixing and is in the prior art typically set at 8-12 ml/min to allow thorough mixing, thereby obtaining small LNP's for direction to the liver.
- the FRW is set to be much lower, thereby obtaining larger LNP's suitable for use in the context of the invention.
- the FRR Flow Rate Ratio
- the FRR is the ratio between lipids in the alcoholic phase and nucleic acids in the watery phase, and is in the invention typically set at about 2/1 to about 3/1.
- LNPs were composed of 50 mol % ⁇ -D-Tocopherolhemisuccinoyl (ionizable lipid), 10 mol % DOPE, 38.5 mol % cholesterol and 1.5 mol % DSG-PEG5000 (PEGylated lipid) at the indicated lipid ratio's (mol %).
- LNPs were produced on a Nano-Assemblr using different flow rates (FR; ml/min) and water/ethanol volume ratio's (FRR). 140 nm sized LNPs were produced at FR 4 ml/min whereas 230 nm sized LNPs were generated at FR 1 ml/min.
- FIG. 1 shows the percentage of OVA-specific CD8+ T cells upon single intravenous administration in mice with OVA/TriMix mRNA LNPs (OVA: 10 ⁇ g; TriMix mRNA: 15 ⁇ g).
- OVA OVA/TriMix mRNA LNPs
- FIG. 1 shows the immunogenicity of the larger LNP's is much higher compared to the immunogenicity of the smaller LNP's.
- the immunogenicity of OVA mRNA LNPs of different size and composition after intravenous administration in mice was determined. All LNPs were composed of ⁇ -D-Tocopherolhemisuccinoyl (ionizable lipid), DOPE, cholesterol and DSG-PEG5000 at the indicated lipid ratio's (mol %), as defined in FIG. 2 . LNPs were produced on a Nano-Assemblr using different flow rates (FR; ml/min) and water/ethanol volume ratio's (FRR), as also defined in FIG. 2 . Percentages of OVA-specific CD8 T cells were quantified by flow cytometry 6 days post immunization. Again as is very clear from FIG. 2 , the immunogenicity of the larger LNP's is higher compared to the immunogenicity of the smaller LNP's.
- the immunogenicity of OVA mRNA LNPs of different sizes and composition after single intravenous administration in mice was determined.
- the plot depicts the number of IFN- ⁇ secreting CD8+ T cells/million splenocytes after restimulation of splenocytes with the OVA MHCI epitope SIINFEKL (5 ⁇ g/ml).
- All LNPs were composed of ⁇ -D-Tocopherolhemisuccinoyl (ionizable lipid), DOPE, cholesterol and DSG-PEG5000 at the indicated lipid ratio's (mol %), as defined in FIG. 3 .
- LNPs were produced on a Nano-Assemblr using different flow rates (FR; ml/min) and water/ethanol volume ratio's (FRR), as also defined in FIG. 3 . Percentages of OVA-specific CD8+ T cells were quantified by flow cytometry 6 days post immunization.
- LNPs were composed of 50 mol % ⁇ -D-Tocopherolhemisuccinoyl (ionizable lipid), 10 mol % DOPE (phospholipid), 38 mol % cholesterol and 1.5 mol % DSG-PEG5000 at the indicated lipid ratio's (mol %), as defined in FIG. 5 .
- LNPs contained 10 ⁇ g of OVA mRNA and 15 ⁇ g of TriMix mRNA (CD40L, CD70 and caTLR4). Percentanges of OVA-specific CD8 T cells responses were measured five days post immunization.
- LNPs were composed of ⁇ -D-Tocopherolhemisuccinoyl (ionizable lipid), DOPC, cholesterol and DSG-PEG5000 at respective lipid ratios of 50/10/38, 5/1,5.
- LNPs of differential sizes were generated by using different flow rates of microfluidic mixing (FR1 versus FR4).
- the figure depicts the ratio of spleen to liver expression of Fluc mRNA, measured by in vivo bioluminescence of ph/s/cm 2 /sr.
- FIGS. 7 A and 7 B The results of this experiment are shown in FIGS. 7 A and 7 B , which clearly show that the used intravenous approach using mRNA LNPs is superior over the intranodal approach, both in terms of immunogenicity and anti-tumor efficacy. Moreover, there appears to be a correlation between the magnitude of the T cell response and the anti-tumor efficacy.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This application is filed as a continuation of U.S. application Ser. No. 16/961,843 filed on Jul. 13, 2020, which is a national stage entry of PCT/EP2019/051261 filed on Jan. 18, 2019, which claims priority to EP application 18152390.3 filed Jan. 18, 2018 and EP application 19150351.5 filed Jan. 4, 2019.
- The present invention relates to the field of lipid nanoparticles (LNP); more specifically comprising an ionisable lipid, a phospholipid, a sterol, a PEG lipid and one or more nucleic acids. The LNP's of the present invention are characterized in having a minimal average diameter of about 140 nm, thereby inducing a more potent immune response. The present invention provides use of the LNPs for immunogenic delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in vaccines, such as for the treatment of cancer or infectious diseases. Finally, methods are provided for preparing such LNP's.
- One of the major challenges in the field of targeted delivery of biologically active substances is often their instability and low cell penetrating potential. This is specifically the case for the delivery of nucleic acid molecules, in particular (m)RNA molecules. Therefore, proper packaging is crucial for adequate protection and delivery. Hence, there is a continuous need for methods and compositions for packaging biologically active substances, such as nucleic acids.
- In that respect, lipid-based nanoparticle compositions such as lipoplexes and liposomes have been used as packaging vehicles for biologically active substances to allow transport into cells and/or intracellular compartments. These lipid-based nanoparticle compositions typically comprise a mixture of different lipids such as cationic lipids, ionizable lipids, phospholipids, structural lipids (such 30 as sterols or cholesterol), PEG (polyethylene glycol) lipids, . . . (as reviewed in Reichmuth et al., 2016). While many of such lipid compositions are known in the art, these typically have a small diameter, i.e. less than 200 nm, most often even less then 140 nm.
- Lipid based nanoparticles composed of a mixture of 4 lipids—a cationic or ionizable lipid, a 35 phospholipid, a sterol and a PEGylated lipid—have been developed for the non-immunogenic delivery of siRNA and mRNA to the liver after systemic administration. To evoke optimal hepatocyte uptake and expression, these LNPs typically display small sizes between 70-100 nm (Li et al., Nanoletters 2015; Thess et al. Mol ther 2015; Kauffman et al. Biomaterials 2016).
- Beyond liver targeting, LNPs have also been used for the immunogenic delivery of antigen encoding mRNA to the muscle or dermis (Richner et al. Cell 2017; Liang et al., Mol Ther 2017). In this case, again small size (80-120 nm) LNPs are typically used since such small sizes have been shown to be crucial for immunogenicity, and small sized LNPs efficiently reach the injection draining lymph node, whereas larger LNP's are retained at the injection site (see Reichmuth et al., 2016).
- We have now surprisingly found that in contrast to the general belief that small-sized particles are beneficial for LNP mediated mRNA delivery, nanoparticles having a diameter of more than 140 nm, preferably even more than 200 nm are highly suitable for immunogenic delivery of mRNA upon systemic injection of the LNPs, which appears to correlate with an enhanced delivery of mRNA to the spleen.
- In a first aspect, the present invention provides a lipid nanoparticle (LNP) comprising an ionisable lipid, a phospholipid, a sterol, a PEG lipid and one or more nucleic acid molecules; characterized in that said LNP has a minimal average diameter of about 140 nm; more preferably of about 200 nm.
- In a specific embodiment, said ionisable lipid is a compound of formula (I):
-
- wherein:
- RCOO is selected from the list comprising: myristoyl, α-D-Tocopherolsuccinoyl, linoleoyl and oleoyl; and
- X is selected from the list comprising:
- More specifically, said ionisable lipid is a lipid of formula (I) wherein RCCO is α-D-Tocopherolsuccinoyl and X is
- In a further embodiment of the present invention, said sterol is selected from the list comprising cholesterol, ergosterol, campesterol, oxysterol, antrosterol, desmosterol, nicasterol, sitosterol and stigmasterol; preferably cholesterol.
- In another specific embodiment, said phospholipid is selected from the list comprising: 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (
C 16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), sphingomyelin, and mixtures thereof. - In a more specific embodiment, said phospholipid is selected from the list comprising: 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), and mixtures thereof.
- In yet a further embodiment, said PEG lipid is selected from the list comprising: PEG-modified phosphatidylethanolamine, a PEG-modified phosphatidic acid, a PEG-modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof.
- In another specific embodiment, one or more of the following applies:
-
- said LNP comprises about and between 10 mol % and 60 mol % of said ionisable lipid;
- said LNP comprises about and between 15 mol % and 50 mol % of said sterol;
- said LNP comprises about and between 0.5 mol % and 10 mol % of said PEG lipid; and/or
- said LNP comprises about and between 5 mol % and 40 mol % of said phospholipid.
- In another specific embodiment, said one or more nucleic acid molecules, are selected from (m)RNA and DNA molecules; more in particular one or more mRNA molecules. In a specific embodiment, said one or more mRNA molecules are selected from the list comprising mRNA molecules encoding immunomodulatory polypeptides such as (add a list of all potential molecules) and/or mRNA molecules encoding antigen- and/or disease-specific mRNA. In a very specific embodiment, said one or more mRNA molecules are selected from the list comprising mRNA molecules encoding for CD40L, CD70 and caTLR4; and/or mRNA molecules encoding antigen- and/or disease-specific mRNA.
- The present invention also provides a pharmaceutical composition or a vaccine comprising one or more LNP's as defined herein.
- Furthermore, the present invention provides an LNP as defined herein or a pharmaceutical composition comprising one or more of such LNP's for use in human or veterinary medicine.
- In a further aspect, the present invention provides a method for the preparation of an LNP according to the invention, comprising:
-
- preparing a first alcoholic composition comprising said ionisable lipid, said phospholipid, said sterol, said PEG lipid, and a suitable alcoholic solvent;
- preparing a second aqueous composition comprising said one or more nucleic acids and an aqueous solvent;
- mixing said first and second composition in a in a microfluidic mixing device using the following settings:
- Total Flow Rate (FR) of about 0.5 to about 8 ml/min, preferably of about 1 to 4 ml/min.
- Flow Rate Ratio (FRR) of about 1/1 to 5/1, preferably of about 2/1 to about 3/1.
- In a specific embodiment, said alcoholic solvent is ethanol and/or said aqueous solvent is water.
- The present invention further provides the use of an LNP, a pharmaceutical composition or a vaccine according to the present invention for the immunogenic delivery of said one or more nucleic acid molecules.
- Finally, the present invention provides an LNP, a pharmaceutical composition, or a vaccine as herein for use in the prevention and/or treatment of cancer or infectious diseases.
- With specific reference now to the figures, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the different embodiments of the present invention only. They are presented in the cause of providing what is believed to be the most useful and readily description of the principles and conceptual aspects of the invention. In this regard no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention. The description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.
-
FIG. 1 : Immunogenicity of 140 nm versus 230 nm sized mRNA LNPs of identical composition. -
FIG. 2 : Immunogenicity of OVA mRNA LNPs of different sizes after intravenous administration. -
FIG. 3 : Immunogenicity of OVA mRNA LNPs of different sizes after single intravenous administration. -
FIG. 4 : Percentages of OVA specific T cells upon intravenous administration of large sized LNPs containing OVA mRNA (10 μg) and TriMix mRNA (15 μg). -
FIG. 5 : Comparison of the immunogenicity of 140 nm and 230 nm sized mRNA LNPs after one and two intravenous administrations of mRNA LNPs. -
FIG. 6 : Comparison ratio spleen/liver expression of 100 nm and 230 nm sized mRNA LNPs -
FIGS. 7A and 7B : Comparison of intravenous LNP mRNA vs intranodal administration -
FIG. 8 : T cell responses to LNP mRNA formulations are long-live and boostable. -
FIG. 9 : Comparison of immunogenicity and T cell response of LNPs having average sizes of 150 nm or 200 nm with LNPs having average size of 100 nm. - As already detailed herein above, the present invention provides LNP's having a diameter which is larger than generally used in the field, for which we have surprisingly found that these are highly suitable for immunogenic delivery of nucleic acid, specifically mRNA; for which we found a correlation with enhanced delivery to the spleen. “immunogenic delivery of nucleic acid molecules” means delivery of nucleic acid molecules to cells whereby contact with cells, internalization and/or expression inside the cells of said nucleic acids molecules result in induction of an immune response.
- Therefore, in a first aspect, the present invention provides a lipid nanoparticle (LNP) comprising an ionisable lipid, a phospholipid, a sterol, a PEG lipid and one or more nucleic acid molecules; characterized in that said LNP has a minimal diameter of about 140 nm; more preferably of about 200 nm.
- A lipid nanoparticle (LNP) is generally known as a nanosized particle composed of a combination of different lipids. While many different types of lipids may be included in such LNP, the LNP's of the present invention are typically composed of a combination of an ionisable lipid, a phospholipid, a sterol and a PEG lipid.
- As used herein, the term “nanoparticle” refers to any particle having a diameter making the particle suitable for systemic, in particular intravenous administration, of, in particular, nucleic acids, typically having a diameter of less than 1000 nanometers (nm).
- In some embodiments, a nanoparticle has an average diameter of less than 600 nm. In some embodiments, a nanoparticle has an average diameter of less than 400 nm, but in any case the nanoparticles of the present invention have an average diameter of more than about 140 nm, more preferably more than about 200 nm. In a specific embodiment, the LNP's of the invention have a minimal average diameter of about 140 nm, about 150 nm, about 160 nm, about 170 nm, about 180 nm, about 190 nm or about 200 nm. For the sake of clarity, where a mixture of multiple LNP's is used, the minimal average diameter as referred to, is meant to be the minimal average diameter of said multiple LNP's. In said instance, for example the mixture may contain some LNP's having a smaller average diameter than 140 nm, in as far as the remainder of the LNP's has an average diameter larger than 140 nm to result in an average minimum diameter of 140 nm of all LNP's together. Whenever used in this application the term “diameter” is meant to be the “average diameter”, even if it is not specifically specified.
- In the context of the present invention the term “ionisable” (or alternatively cationic) in the context of a compound or lipid means the presence of any uncharged group in said compound or lipid which is capable of dissociating by yielding an ion (usually an H+ ion) and thus itself becoming positively charged. Alternatively, any uncharged group in said compound or lipid may yield an electron and thus becoming negatively charged.
- In the context of the present invention any type of ionizable lipid can suitably be used. Specifically, suitable ionizable lipids are ionizable amino lipids which comprise 2 identical or different tails linked via an S—S bond, each of said tails comprising an ionizable amine such as represented by
- In a specific embodiment, said ionisable lipid is a compound of formula (I):
-
- wherein:
- RCOO is selected from the list comprising: myristoyl, α-D-Tocopherolsuccinoyl, linoleoyl and oleoyl; and
- X is selected from the list comprising:
- Such ionisable lipids are specifically represented by anyone of the following formulae:
- More specifically, said ionisable lipid is a lipid of formula (I) wherein RCCO is α-D-Tocopherolsuccinoyl and X is
- such as represented by
- In the context of the present invention, the term “sterol”, also known as steroid alcohol, is a subgroup of steroids that occur naturally in plants, animal and fungi, or can be produced by some bacteria. In the context of the present invention, any suitable sterol may be used, such as selected from the list comprising cholesterol, ergosterol, campesterol, oxysterol, antrosterol, desmosterol, nicasterol, sitosterol and stigmasterol; preferably cholesterol.
- In the context of the present invention the term “phospholipid” is meant to be lipid molecule consisting of two hydrophobic fatty acid “tails” and a hydrophilic “head” consisting of a phosphate groups. The two components are most often joined together by a glycerol molecule, hence, in the phospholipid of the present invention is preferably a glycerol-phospholipid. Furthermore, the phosphate group is often modified with simple organic molecules such as choline (i.e. rendering a phosphocholine) or ethanolamine (i.e. rendering a phosphoethanolamine).
- Suitable phospholipids within the context of the invention can be selected from the list comprising: 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C 16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), sphingomyelin, and mixtures thereof.
- In a more specific embodiment, said phospholipid is selected from the list comprising: 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), and mixtures thereof.
- In the context of the present invention, the term “PEG lipid” or alternatively “PEGylated lipid” is meant to be any suitable lipid modified with a PEG (polyethylene glycol) group. In a particular embodiment, said PEG lipid is selected from the list comprising: PEG-modified phosphatidylethanolamine, a PEG-modified phosphatidic acid, a PEG-modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof. More specific examples of such PEG lipids encompass C14-PEG2000 (1,2-Dimyristoyl-rac-glycerol, methoxypolyethylene glycol-2000 (DMG-PEG2000)) and C18-PEG5000 (1,2-Distearoyl-rac-glycerol, methoxypolyethylene glycol-5000 (DSG-PEG5000)).
- In a specific embodiment of the present invention one or more of the following applies:
-
- said LNP comprises about and between 35 mol % and 65 mol % of said ionisable lipid;
- said LNP comprises about and between 15 mol % and 60 mol % of said sterol;
- said LNP comprises about and between 0.5 mol % and 2 mol % of said PEG lipid; and/or
- said LNP comprises about and between 5 mol % and 15 mol % of said phospholipid.
- In another specific embodiment of the present invention one or more of the following applies:
-
- said LNP comprises about and between 10 mol % and 60 mol % of said ionisable lipid;
- said LNP comprises about and between 15 mol % and 50 mol % of said sterol;
- said LNP comprises about and between 0.5 mol % and 10 mol % of said PEG lipid; and/or
- said LNP comprises about and between 5 mol % and 40 mol % of said phospholipid.
- In a more specific embodiment, one or more of the following applies:
-
- said LNP comprises about and between 40 mol % and 60 mol % of said ionisable lipid;
- said LNP comprises about and between 20 mol % and 40 mol % of said sterol;
- said LNP comprises about and between 0.5 mol % and 5 mol % of said PEG lipid; and/or
- said LNP comprises about and between 5 mol % and 15 mol % of said phospholipid.
- Hence, in a particular embodiment, said LNP comprises about and between 10 mol % and 60 mol % of said ionisable lipid; preferably about and between 40 mol % and 60 mol %.
- In yet another specific embodiment, said LNP comprises about and between 15 mol % and 50 mol % of sterol; preferably about and between 20 mol % and 40 mol %.
- In a further embodiment, said LNP comprises about and between 0.5 mol % and 10 mol % of said PEG lipid; preferably about and between 0.5 mol % and 5 mol %.
- In another specific embodiment, said LNP comprises about and between 5 mol % and 40 mol % of said phospholipid; preferably about and between 5 mol % and 15 mol %.
- Hence, in a more specific embodiment, the LNP of the present invention comprises about and between 10 mol % and 60 mol % of said ionisable lipid; and/or about and between 15 mol % and 50 mol % of sterol; and/or about and between 0.5 mol % and 10 mol % of said PEG lipid; and/or about and between 5 mol % and 40 mol % of said phospholipid.
- In another specific embodiment, the LNP of the present invention comprises about and between 40 mol % and 60 mol % of said ionisable lipid; and about and between 20 mol % and 40 mol % of sterol; and about and between 0.5 mol % and 5 mol % of said PEG lipid; and about and between 5 mol % and 15 mol % of said phospholipid.
- The composition of particularly suitable LNP's in the context of the invention is represented in table 1:
-
TABLE 1 Composition of particularly suitable LNP's Ionizable Phospholipid Cholesterol PEG Lipid Type of Type of No Lipid (mol %) (mol %) (mol %) (mol %) Phospholipid PEG Lipid 1 65 15 18 2 DOPC C14PEG2000 2 50 15 33 2 DOPE C14PEG2000 3 35 5 59.5 0.5 DOPE C18- PEG5000 4 65 5 28 2 DOPC C18- PEG5000 5 50 10 39 1 DOPC C14PEG2000 6 35 15 49.5 0.5 DOPE C14PEG2000 7 50 10 39 1 DOPE C18-PEG5000 8 50 5 44.5 0.5 DOPC C18-PEG5000 9 35 5 59 1 DOPC C14PEG2000 10 65 15 19 1 DOPE C18-PEG5000 11 35 15 49.5 0.5 DOPC C14PEG2000 12 50 10 39 1 DOPE C14PEG2000 13 65 5 29.5 0.5 DOPC C14PEG2000 14 35 15 48 2 DOPE C18- PEG5000 15 35 10 53 2 DOPC C18- PEG5000 16 35 5 58 2 DOPE C14PEG2000 17 65 5 28 2 DOPE C18-PEG5000 18 65 15 19.5 0.5 DOPC C18-PEG5000 19 65 10 24.5 0.5 DOPE C14PEG2000 20 50 10 39 1 DOPC C18-PEG5000 - The inventors have found that the LNP's of the present invention are particularly suitable for the immunogenic delivery of nucleic acids; due to an increased targeting of the spleen in contrast to prior art known small LNP's which are mainly found to target the liver.
- Hence the present invention provides LNP's comprising one or more nucleic acid molecules, such as DNA or RNA, more specifically mRNA.
- A “nucleic acid” in the context of the invention is a deoxyribonucleic acid (DNA) or preferably a ribonucleic acid (RNA), more preferably mRNA. Nucleic acids include according to the invention genomic DNA, cDNA, mRNA, recombinantly produced and chemically synthesized molecules. A nucleic acid may according to the invention be in the form of a molecule which is single stranded or double stranded and linear or closed covalently to form a circle. A nucleic can be employed for introduction into, i.e. transfection of, cells, for example, in the form of RNA which can be prepared by in vitro transcription from a DNA template. The RNA can moreover be modified before application by stabilizing sequences, capping, and polyadenylation.
- In the context of the present invention, the term “RNA” relates to a molecule which comprises ribonucleotide residues and preferably being entirely or substantially composed of ribonucleotide residues. “Ribonucleotide” relates to a nucleotide with a hydroxyl group at the 2′-position of a β-D-ribofuranosyl group. The term includes double stranded RNA, single stranded RNA, isolated RNA such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA, as well as modified RNA that differs from naturally occurring RNA by the addition, deletion, substitution and/or alteration of one or more nucleotides. Such alterations can include addition of non-nucleotide material, such as to the end(s) of a RNA or internally, for example at one or more nucleotides of the RNA. Nucleotides in RNA molecules can also comprise non-standard nucleotides, such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These altered RNAs can be referred to as analogs. Nucleic acids may be comprised in a vector. The term “vector” as used herein includes any vectors known to the skilled person including plasmid vectors, cosmid vectors, phage vectors such as lambda phage, viral vectors such as adenoviral or baculoviral vectors, or artificial chromosome vectors such as bacterial artificial chromosomes (BAC), yeast artificial or analogs of naturally-occurring RNA.
- According to the present invention, the term “RNA” includes and preferably relates to “mRNA” which means “messenger RNA” and relates to a “transcript” which may be produced using DNA as template and encodes a peptide or protein, mRNA typically comprises a 5′ untranslated region (5-UTR), a protein or peptide coding region and a 3′ untranslated region (3′-UTR). mRNA has a limited halftime in cells and in vitro. Preferably, mRNA is produced by in vitro transcription using a DNA template. In one embodiment of the invention, the RNA is obtained by in vitro transcription or chemical synthesis. The in vitro transcription methodology is known to the skilled person. For example, there is a variety of in vitro transcription kits commercially available.
- In a specific embodiment said mRNA molecules are mRNA molecules encoding immune modulating proteins.
- In the context of the present invention, the term “mRNA molecules encoding immune modulating proteins” is meant to be mRNA molecules encoding proteins that modify the functionality of antigen presenting cells; more in particular dendritic cells. Such molecules may be selected from the list comprising CD40L, CD70, caTLR4, IL-12p70, EL-selectin, CCR7, and/or 4-1 BBL, ICOSL, OX40L, IL-21; more in particular one or more of CD40L, CD70 and caTLR4. A preferred combination of immunostimulatory factors used in the methods of the invention is CD40L and caTLR4 (i.e. “DiMix”). In another preferred embodiment, the combination of CD40L, CD70 and caTLR4 immunostimulatory molecules is used, which is herein also named “TriMix”
- In another specific embodiment said mRNA molecules are mRNA molecules encoding antigen- and/or disease-specific proteins.
- According to the present invention, the term “antigen” comprises any molecule, preferably a peptide or protein, which comprises at least one epitope that will elicit an immune response and/or against which an immune response is directed. Preferably, an antigen in the context of the present invention is a molecule which, optionally after processing, induces an immune response, which is preferably specific for the antigen or cells expressing the antigen. In particular, an “antigen” relates to a molecule which, optionally after processing, is presented by MHC molecules and reacts specifically with T lymphocytes (T cells).
- In a specific embodiment, the antigen is a target-specific antigen which can be a tumor antigen, or a bacterial, viral or fungal antigen. Said target-specific antigen can be derived from either one of: total mRNA isolated from (a) target cell(s), one or more specific target mRNA molecules, protein lysates of (a) target cell(s), specific proteins from (a) target cell(s), or a synthetic target-specific peptide or protein and synthetic mRNA or DNA encoding a target-specific antigen or its derived peptides.
- To avoid any misunderstanding the LNP's of the present invention may comprise a single mRNA molecules, or they may comprise multiple mRNA molecules, such as a combination of one or more mRNA molecules encoding immune modulating proteins and/or one or more mRNA molecules encoding antigen- and/or disease-specific proteins.
- In a very specific embodiment, said mRNA molecules encoding immunomodulatory molecules may be combined with one or more mRNA molecules encoding antigen- and/or disease-specific proteins. For example, the LNP's of the present invention may comprise mRNA molecules encoding the immunostimulatory molecules CD40L, CD70 and/or caTLR4 (such as Dimix or Trimix); in combination with one or more mRNA molecules encoding antigen- and/or disease-specific proteins. Thus, in a very specific embodiment, the LNP's of the present invention comprise an mRNA molecule encoding CD40L, CD70 and/or caTLR4; in combination with one or more mRNA molecules encoding antigen- and/or disease-specific proteins.
- In a further aspect, the present invention provides a pharmaceutical composition comprising one or more LNP's as defined herein. Such pharmaceutical compositions are particularly suitable as a vaccine. Thus, the invention also provides a vaccine comprising one or more LNP's according to the present invention.
- In the context of the present invention, the term “vaccine” as used herein is meant to be any preparation intended to provide adaptive immunity (antibodies and/or T cell responses) against a disease. To that end, a vaccine as meant herein contains at least one mRNA molecule encoding an antigen to which an adaptive immune response is mounted. This antigen can be present in the format of a weakened or killed form of a microbe, a protein or peptide, or an antigen encoding a nucleic acid. An antigen in the context of this invention is meant to be a protein or peptide recognized by the immune system of a host as being foreign, thereby stimulating the production of antibodies against is, with the purpose of combating such antigens. Vaccines can be prophylactic (example: to prevent or ameliorate the effects of a future infection by any natural or “wild” pathogen), or therapeutic (example, to actively treat or reduce the symptoms of an ongoing disease). The administration of vaccines is called vaccination.
- The vaccine of the invention may be used for inducing an immune response, in particular an immune response against a disease-associated antigen or cells expressing a disease-associated antigen, such as an immune response against cancer. Accordingly, the vaccine may be used for prophylactic and/or therapeutic treatment of a disease involving a disease-associated antigen or cells expressing a disease-associated antigen, such as cancer. Preferably said immune response is a T cell response. In one embodiment, the disease-associated antigen is a tumor antigen. The antigen encoded by the RNA comprised in the nanoparticles described herein preferably is a disease-associated antigen or elicits an immune response against a disease-associated antigen or cells expressing a disease-associated antigen.
- The LNP's and vaccines of the present invention are specifically intended for intravenous administration, i.e. the infusion of liquid substance directly into a vein. The intravenous route is the fastest way to deliver fluids and medications throughout the body, i.e. systemically. The present invention thus provides intravenous vaccines, as well as the use of the disclosed vaccines and LNP's for intravenous administration. The vaccines and LNP's of the present invention can thus be administered intravenously. The present invention also provides the use of the vaccines and LNP's according to the present invention; wherein the vaccine is administered intravenously.
- The present invention also provides the LNP's, pharmaceutical compositions and vaccines according to this invention for use in human or veterinary medicine. The use of the LNP's, pharmaceutical compositions and vaccines according to this invention for human or veterinary medicine is also intended. Finally, the invention provides a method for the prophylaxis and treatment of human and veterinary disorders, by administering the LNP's, pharmaceutical compositions and vaccines according to this invention to a subject in need thereof.
- The present invention further provides the use of an LNP, a pharmaceutical composition or a vaccine according to the present invention for the immunogenic delivery of said one or more nucleic acid molecules. This effect is specifically achieved using the larger LNP's of the invention, due to their preferential targeting to the spleen. The small-sized LNP's of the prior art where found to preferentially target the liver, thereby having little or no immunogenic effect. As such the LNP's, pharmaceutical compositions and vaccine of the present invention are highly useful in the treatment several human and veterinary disorders. Thus, the present invention provides the LNP's, pharmaceutical compositions and vaccines of the present invention for use in the treatment of cancer or infectious diseases.
- In a further aspect, the present invention provides methods for the preparation of an LNP according to the present invention, comprising:
-
- preparing a first alcoholic composition comprising said ionisable lipid, said phospholipid, said sterol, said PEG lipid, and a suitable alcoholic solvent;
- preparing a second aqueous composition comprising said one or more nucleic acids and an aqueous solvent;
- mixing said first and second composition in a in a microfluidic mixing device using the following settings:
- Total Flow Rate (FR) of about 0.5 to about 8 ml/min, preferably of about 1 to 4 ml/min.
- Flow Rate Ratio (FRR) of about 1/1 to 5/1, preferably of about 2/1 to about 3/1
- In further detail, the lipid components are combined in suitable concentrations in an alcoholic vehicle such as ethanol. Thereto, an aqueous composition comprising the nucleic acid is added, and subsequently loaded in a microfluidic mixing device.
- The aim of microfluidic mixing is to achieve thorough and rapid mixing of multiple samples (i.e. lipid phase and nucleic acid phase) in a microscale device. Such sample mixing is typically achieved by enhancing the diffusion effect between the different species flows. Thereto several microfluidic mixing devices can be used, such as for example reviewed in Lee et al., 2011. A particularly suitable microfluidic mixing device according to the present invention is the NanoAssemblr from Precision Nanosystems.
- The mixing parameters of such microfluidic mixing devices have a large impact on the characteristics of the obtained LNP's, specifically on the size thereof. Hence, to obtain large LNP's i.e. having an average diameter of at least 140 nm, preferably at least 200 nm, the FR and FRR parameters are highly relevant.
- The total FR (Flow Rate) is a measure for the speed of microfluidic mixing and is in the prior art typically set at 8-12 ml/min to allow thorough mixing, thereby obtaining small LNP's for direction to the liver. In contrast, in the present invention, the FRW is set to be much lower, thereby obtaining larger LNP's suitable for use in the context of the invention.
- The FRR (Flow Rate Ratio) is the ratio between lipids in the alcoholic phase and nucleic acids in the watery phase, and is in the invention typically set at about 2/1 to about 3/1.
- In this first example, the effect of particle size on the immunogenicity of mRNA LNP's was assessed. Thereto, 140 nm and 230 nm sized mRNA LNPs of identical composition were prepared. LNPs were composed of 50 mol % α-D-Tocopherolhemisuccinoyl (ionizable lipid), 10 mol % DOPE, 38.5 mol % cholesterol and 1.5 mol % DSG-PEG5000 (PEGylated lipid) at the indicated lipid ratio's (mol %). LNPs were produced on a Nano-Assemblr using different flow rates (FR; ml/min) and water/ethanol volume ratio's (FRR). 140 nm sized LNPs were produced at
FR 4 ml/min whereas 230 nm sized LNPs were generated atFR 1 ml/min. -
FIG. 1 shows the percentage of OVA-specific CD8+ T cells upon single intravenous administration in mice with OVA/TriMix mRNA LNPs (OVA: 10 μg; TriMix mRNA: 15 μg). As is very clear fromFIG. 1 , the immunogenicity of the larger LNP's is much higher compared to the immunogenicity of the smaller LNP's. - In this example, the immunogenicity of OVA mRNA LNPs of different size and composition after intravenous administration in mice was determined. All LNPs were composed of α-D-Tocopherolhemisuccinoyl (ionizable lipid), DOPE, cholesterol and DSG-PEG5000 at the indicated lipid ratio's (mol %), as defined in
FIG. 2 . LNPs were produced on a Nano-Assemblr using different flow rates (FR; ml/min) and water/ethanol volume ratio's (FRR), as also defined inFIG. 2 . Percentages of OVA-specific CD8 T cells were quantified byflow cytometry 6 days post immunization. Again as is very clear fromFIG. 2 , the immunogenicity of the larger LNP's is higher compared to the immunogenicity of the smaller LNP's. - In this example, the immunogenicity of OVA mRNA LNPs of different sizes and composition after single intravenous administration in mice was determined. The plot depicts the number of IFN-γ secreting CD8+ T cells/million splenocytes after restimulation of splenocytes with the OVA MHCI epitope SIINFEKL (5 μg/ml). All LNPs were composed of α-D-Tocopherolhemisuccinoyl (ionizable lipid), DOPE, cholesterol and DSG-PEG5000 at the indicated lipid ratio's (mol %), as defined in
FIG. 3 . LNPs were produced on a Nano-Assemblr using different flow rates (FR; ml/min) and water/ethanol volume ratio's (FRR), as also defined inFIG. 3 . Percentages of OVA-specific CD8+ T cells were quantified byflow cytometry 6 days post immunization. - Next, we assessed the effect of varying the PEGylated lipid, thereto, 2 different compositions were made either with DSG-PEG5000 or DMG-PEG2000. Percentages of OVA specific T cells upon intravenous administration of large sized LNPs containing OVA mRNA (10 μg) and TriMix mRNA (15 μg) was determined and represented in
FIG. 4 . Mice were immunized at day 0 andday 20. % OVA-specific T cells were assessed on blood samples atdays FIG. 4 , the type of PEGylated lipid has no effect on the immunogenicity of the LNP's. - In this example, we assessed, the immunogenicity of small and large LNP's after repeated immunization, using 140 nm and 230 nm sized mRNA LNPs (
FIG. 5 ). LNPs were composed of 50 mol % α-D-Tocopherolhemisuccinoyl (ionizable lipid), 10 mol % DOPE (phospholipid), 38 mol % cholesterol and 1.5 mol % DSG-PEG5000 at the indicated lipid ratio's (mol %), as defined inFIG. 5 . LNPs contained 10 μg of OVA mRNA and 15 μg of TriMix mRNA (CD40L, CD70 and caTLR4). Percentanges of OVA-specific CD8 T cells responses were measured five days post immunization. - In this example, we compared mRNA expression in spleen and liver after intravenous injection of mice with Fluc mRNA LNPs of different size—
FIG. 6 ). LNPs were composed of α-D-Tocopherolhemisuccinoyl (ionizable lipid), DOPC, cholesterol and DSG-PEG5000 at respective lipid ratios of 50/10/38, 5/1,5. LNPs of differential sizes were generated by using different flow rates of microfluidic mixing (FR1 versus FR4). The figure depicts the ratio of spleen to liver expression of Fluc mRNA, measured by in vivo bioluminescence of ph/s/cm2/sr. - In this example, we demonstrate that formulated intravenous mRNA LNPs evoke superior immunogenicity and anti-tumor efficacy compared to intranodal approaches.
- The characteristics of the used API are as follows:
-
- E7 mRNA, column purified, 10 jag/administration
- Immunization schedule: 3 times weekly
- The results of this experiment are shown in
FIGS. 7A and 7B , which clearly show that the used intravenous approach using mRNA LNPs is superior over the intranodal approach, both in terms of immunogenicity and anti-tumor efficacy. Moreover, there appears to be a correlation between the magnitude of the T cell response and the anti-tumor efficacy. - In this example, we demonstrate that T cell responses to mRNA LNP formulations are long-lived and boostable.
- Thereto, 3 different formulations where used in the immunization schedules of which the results are shown in
FIG. 8 . From these results, the following observations/conclusions can be made: -
- Extended contraction phase with high % of E7-
specific T cells 40 days afterimmunization 3 - Memory conversion
- Stunning recall response: IV formulation vaccines can be boosted.
- Extended contraction phase with high % of E7-
- In this example, a further experiment demonstrating the effect of the size of the LNPs was performed.
- Thereto, the following experimental settings were used:
-
- Ratio ionizable lipid/chol/DOPE/DMG-PEG2000-50/38,5/10/1,5
- Three immunizations IV; days 0, 7, 14
- mRNA: OVA encoding mRNA, 10 μg/immunization
- Assessment of % OVA specific CD8 T cells at
days
- The results are detailed in
FIG. 9 , and clearly show that LNPs having an average size of 150 nm or 200 nm are clearly much more immunogenic in terms of the T cell response, compared to LNPs having an average size of only 100 nm. -
- Reichmuth et al., 2016—mRNA vaccine delivery using lipid nanoparticles—Therapeutic Delivery Vol. 7,
No 5. - Li et al., 2015—An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo—Nano Letters 15(12) pg. 8099-8107.
- Thess et al., 2015—Sequence-engineered mRNA without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals—Molecules Therapy Vol. 23, Issue 9 μg. 1456-1464.
- Kauffman et al., 2016—Materials for non-viral intracellular delivery of messenger RNA therapeutics—Journal of Controlled Release, Vol. 240, pg. 227-234.
- Richner et al., 2017—Modified mRNA vaccines protect against Zika virus infection—Cell, Vol. 168,
Issue 6 μg. 1114-1125 - Liang et al., 2017—Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques—Molecular Therapy, vol. 25 Issue 12 μg. 2635-2647.
- Lee et al., 2011—Microfluidic Mixing: A Review—Int. J. Mol. Sci. 12(5): pg. 3263-3287.
Claims (17)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/196,235 US20240016738A1 (en) | 2018-01-18 | 2023-05-11 | Lipid nanoparticles |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18152390 | 2018-01-18 | ||
EP18152390.3 | 2018-01-18 | ||
EP19150351.5 | 2019-01-04 | ||
EP19150351 | 2019-01-04 | ||
PCT/EP2019/051261 WO2019141814A1 (en) | 2018-01-18 | 2019-01-18 | Lipid nanoparticles |
US202016961843A | 2020-07-13 | 2020-07-13 | |
US18/196,235 US20240016738A1 (en) | 2018-01-18 | 2023-05-11 | Lipid nanoparticles |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/961,843 Continuation US11684577B2 (en) | 2018-01-18 | 2019-01-18 | Lipid nanoparticles |
PCT/EP2019/051261 Continuation WO2019141814A1 (en) | 2018-01-18 | 2019-01-18 | Lipid nanoparticles |
Publications (1)
Publication Number | Publication Date |
---|---|
US20240016738A1 true US20240016738A1 (en) | 2024-01-18 |
Family
ID=65138998
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/961,843 Active US11684577B2 (en) | 2018-01-18 | 2019-01-18 | Lipid nanoparticles |
US18/196,235 Pending US20240016738A1 (en) | 2018-01-18 | 2023-05-11 | Lipid nanoparticles |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/961,843 Active US11684577B2 (en) | 2018-01-18 | 2019-01-18 | Lipid nanoparticles |
Country Status (6)
Country | Link |
---|---|
US (2) | US11684577B2 (en) |
EP (1) | EP3740241A1 (en) |
JP (1) | JP7333563B2 (en) |
CN (1) | CN111971066A (en) |
CA (1) | CA3088485A1 (en) |
WO (1) | WO2019141814A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019141814A1 (en) * | 2018-01-18 | 2019-07-25 | Etherna Immunotherapies Nv | Lipid nanoparticles |
CN114502269A (en) * | 2019-10-04 | 2022-05-13 | 国立大学法人北海道大学 | Three-dimensional flow channel structure and method for producing nanoparticles using same |
CN114901360A (en) * | 2019-12-20 | 2022-08-12 | 库瑞瓦格股份公司 | Novel lipid nanoparticles for delivery of nucleic acids |
AU2021211894A1 (en) * | 2020-01-21 | 2022-09-01 | Etherna Immunotherapies Nv | Lipid nanoparticles |
CN111467321A (en) * | 2020-03-26 | 2020-07-31 | 深圳市新合生物医疗科技有限公司 | Intracellular delivery system of mRNA nucleic acid medicine, preparation method and application |
JP2023545886A (en) * | 2020-06-11 | 2023-11-01 | イーザアールエヌーエー イムノセラピーズ エンヴェー | lipid nanoparticles |
TW202233232A (en) | 2020-11-06 | 2022-09-01 | 法商賽諾菲公司 | Lipid nanoparticles for delivering mrna vaccines |
EP4251170A1 (en) | 2020-11-25 | 2023-10-04 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
WO2022136641A1 (en) * | 2020-12-23 | 2022-06-30 | Etherna Immunotherapies Nv | Ionizable lipids |
CN113663089B (en) * | 2021-06-25 | 2022-10-28 | 北京理工大学 | Ionizable lipid nanoparticle composition, preparation method and application |
CN114149337B (en) * | 2021-07-07 | 2022-04-29 | 天津键凯科技有限公司 | Novel ionizable lipid for nucleic acid delivery and LNP composition thereof |
CN113941011A (en) * | 2021-10-15 | 2022-01-18 | 浙江汇科泽华生物技术有限公司 | Nano liposome particle containing ionizable cationic lipid and preparation method thereof |
CN115304756B (en) * | 2022-01-30 | 2023-05-09 | 上海科技大学 | Five-membered lipid nanoparticle as well as preparation method and application thereof |
US11951177B2 (en) | 2022-03-23 | 2024-04-09 | Nanovation Therapeutics Inc. | High sterol-containing lipid nanoparticles |
TW202400189A (en) * | 2022-05-20 | 2024-01-01 | 比利時商eTheRNA免疫治療公司 | Ionizable lipids |
US12064479B2 (en) | 2022-05-25 | 2024-08-20 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
WO2024115353A1 (en) * | 2022-11-28 | 2024-06-06 | Eth Zurich | Analytical composition for monitoring disinfection |
CN116083463B (en) * | 2022-12-16 | 2024-06-21 | 四川大学华西医院 | MRNA for enhancing immunotherapy effect and application thereof in preparing mRNA vaccine |
WO2024131810A1 (en) * | 2022-12-21 | 2024-06-27 | Suzhou Abogen Biosciences Co., Ltd. | Lipid nanoparticles comprising sterol-modified phospholipids |
CN115998714B (en) * | 2023-03-20 | 2023-06-30 | 威瑞生物科技(昆明)有限责任公司 | Lipid nanoparticle, delivery system and preparation method of delivery system |
CN116589595B (en) * | 2023-05-10 | 2024-07-19 | 山东大学 | Targeting MRSA chimeric antigen receptor, drug delivery body, CAR-macrophage and application |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030053978A1 (en) * | 1996-02-16 | 2003-03-20 | Max-Planck-Gesselschaft Zur Forderung Der Wissenschaften E.V. | Phosphatidyl oligoglycerols |
US20120276209A1 (en) * | 2009-11-04 | 2012-11-01 | The University Of British Columbia | Nucleic acid-containing lipid particles and related methods |
WO2012170930A1 (en) * | 2011-06-08 | 2012-12-13 | Shire Human Genetic Therapies, Inc | Lipid nanoparticle compositions and methods for mrna delivery |
US20160250323A1 (en) * | 2013-09-26 | 2016-09-01 | Biontech Ag | Particles Comprising a Shell with RNA |
US20170340724A1 (en) * | 2015-10-22 | 2017-11-30 | Modernatx, Inc. | Zika virus rna vaccines |
WO2019077053A1 (en) * | 2017-10-20 | 2019-04-25 | Biontech Rna Pharmaceuticals Gmbh | Preparation and storage of liposomal rna formulations suitable for therapy |
US11684577B2 (en) * | 2018-01-18 | 2023-06-27 | Etherna Immunotherapies Nv | Lipid nanoparticles |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008519042A (en) * | 2004-11-03 | 2008-06-05 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | Influenza vaccination |
US20110165223A1 (en) * | 2008-01-02 | 2011-07-07 | The Johns Hopkins University | Antitumor Immunization by Liposomal Delivery of Vaccine to the Spleen |
TW201004658A (en) * | 2008-07-31 | 2010-02-01 | Enzon Pharmaceuticals Inc | Nanoparticle compositions for nucleic acids delivery system |
PL4008357T3 (en) * | 2010-08-31 | 2023-03-06 | Glaxosmithkline Biologicals Sa | Small liposomes for delivery of immunogen-encoding rna |
EP2718269B1 (en) | 2011-06-08 | 2018-01-31 | Translate Bio, Inc. | Cleavable lipids |
WO2013073480A1 (en) | 2011-11-18 | 2013-05-23 | 日油株式会社 | Cationic lipid having improved intracellular kinetics |
US20140363493A1 (en) * | 2013-06-10 | 2014-12-11 | Albert Einstein College Of Medicine Of Yeshiva University | LIPID NANOPARTICLES FOR TARGETED siRNA DELIVERY |
CN107406396B (en) * | 2015-01-30 | 2021-02-26 | 日油株式会社 | Cationic lipid |
ES2810701T5 (en) * | 2015-10-05 | 2024-07-11 | Modernatx Inc | Procedures for the therapeutic administration of messenger ribonucleic acid drugs |
WO2017192470A1 (en) * | 2016-05-03 | 2017-11-09 | Merck Sharp & Dohme Corp. | Combination therapy of anti-il-10 antibody and compositions comprising lipid nanoparticles and tlr9 agonist cpg oligonucleotides |
-
2019
- 2019-01-18 WO PCT/EP2019/051261 patent/WO2019141814A1/en unknown
- 2019-01-18 US US16/961,843 patent/US11684577B2/en active Active
- 2019-01-18 CA CA3088485A patent/CA3088485A1/en active Pending
- 2019-01-18 CN CN201980015578.5A patent/CN111971066A/en active Pending
- 2019-01-18 JP JP2020560556A patent/JP7333563B2/en active Active
- 2019-01-18 EP EP19701206.5A patent/EP3740241A1/en active Pending
-
2023
- 2023-05-11 US US18/196,235 patent/US20240016738A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030053978A1 (en) * | 1996-02-16 | 2003-03-20 | Max-Planck-Gesselschaft Zur Forderung Der Wissenschaften E.V. | Phosphatidyl oligoglycerols |
US20120276209A1 (en) * | 2009-11-04 | 2012-11-01 | The University Of British Columbia | Nucleic acid-containing lipid particles and related methods |
WO2012170930A1 (en) * | 2011-06-08 | 2012-12-13 | Shire Human Genetic Therapies, Inc | Lipid nanoparticle compositions and methods for mrna delivery |
US20160250323A1 (en) * | 2013-09-26 | 2016-09-01 | Biontech Ag | Particles Comprising a Shell with RNA |
US20170340724A1 (en) * | 2015-10-22 | 2017-11-30 | Modernatx, Inc. | Zika virus rna vaccines |
WO2019077053A1 (en) * | 2017-10-20 | 2019-04-25 | Biontech Rna Pharmaceuticals Gmbh | Preparation and storage of liposomal rna formulations suitable for therapy |
US11684577B2 (en) * | 2018-01-18 | 2023-06-27 | Etherna Immunotherapies Nv | Lipid nanoparticles |
Non-Patent Citations (5)
Title |
---|
Anil B. Jindal. "Nanocarriers for spleen targeting: anatomo-physiological considerations, formulation strategies and therapeutic potential." Drug Delivery and Translational Research, Vol. 6, 2016, pages 473-485. (Year: 2016) * |
Aude Bonehill et al. "Enhancing the T-cell Stimulatory Capacity of Human Dendritic Cells by Co-electroporation With CD40L, CD70 and Constitutively Active TLR4 Encoding mRNA." Molecular Therapy, Vol. 16, No. 6, June 2008, pages 1170-1180. (Year: 2008) * |
Hidetaka Akita et al. "Molecular Tuning of a Vitamin E‑Scaffold pH-Sensitive and Reductive Cleavable Lipid-like Material for Accelerated in Vivo Hepatic siRNA Delivery." ACS Biomaterials Science & Engineering, Vol. 1, 2015, pages 834-844 and S1-S17. (Year: 2015) * |
Norbert Pardi et al. "Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes." Journal of Controlled Release 217 (2015) pages 345–351. (Year: 2015) * |
Patrick Midoux and Chantal Pichon. "Lipid-based mRNA vaccine delivery systems." Expert Review of Vaccines, Vol. 14(2), 2015, pages 221-234. (Year: 2015) * |
Also Published As
Publication number | Publication date |
---|---|
CA3088485A1 (en) | 2019-07-25 |
JP2021511376A (en) | 2021-05-06 |
JP7333563B2 (en) | 2023-08-25 |
US20200345641A1 (en) | 2020-11-05 |
CN111971066A (en) | 2020-11-20 |
EP3740241A1 (en) | 2020-11-25 |
WO2019141814A1 (en) | 2019-07-25 |
US11684577B2 (en) | 2023-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240016738A1 (en) | Lipid nanoparticles | |
Guevara et al. | Advances in lipid nanoparticles for mRNA-based cancer immunotherapy | |
US11235069B2 (en) | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo | |
US20230149310A1 (en) | Lipid particles for nucleic acid delivery | |
JP4535211B2 (en) | Cocreate delivery vehicle | |
US20060252717A1 (en) | Sphingoid polyalkylamine conjugates for vaccination | |
US20230067722A1 (en) | Lipid nanoparticles | |
JP6703982B2 (en) | Stable formulation of lipids and liposomes | |
US20220001025A1 (en) | RNA Particles Comprising Polysarcosine | |
US7906122B2 (en) | Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination | |
US20240261381A1 (en) | Lipid nanoparticles | |
AU2021379090A1 (en) | Lnp compositions comprising rna and methods for preparing, storing and using the same | |
Kim et al. | Physical and chemical advances of synthetic delivery vehicles to enhance mRNA vaccine efficacy | |
WO2022218503A1 (en) | Lnp compositions comprising rna and methods for preparing, storing and using the same | |
WO2010067617A1 (en) | Lipid membrane structure | |
WO2023036960A1 (en) | Lipid-based rna formulations suitable for therapy | |
AU2022256732A1 (en) | Rna compositions comprising a buffer substance and methods for preparing, storing and using the same | |
US20230355526A1 (en) | Lipid compositions comprising polynucleotide antigens | |
WO2024194454A1 (en) | Stabilized nucleic acid compositions and methods for preparing, storing and using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ETHERNA IMMUNOTHERAPIES NV, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DE KOKER, STEFAAN;BEVERS, SANNE;TOMME, PETER;SIGNING DATES FROM 20180514 TO 20190516;REEL/FRAME:064666/0660 Owner name: VRIJE UNIVERSITEIT BRUSSEL, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ETHERNA IMMUNOTHERAPIES NV;REEL/FRAME:064666/0716 Effective date: 20220712 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |